Company profile: Ash Access Technology
1.1 - Company Overview
Company description
- Provider of technologies and devices to treat and prevent the clinical consequences of vascular access-related diseases, including central line hemodialysis catheters designed to prevent fibrous sheaths, split-tip dialysis catheters, 7% sodium citrate catheter lock solutions, an extracorporeal charcoal-based sorbent liver dialysis system, and skin prep for vascular access procedures.
Products and services
- Ash SplitCath®: A clinical-grade central catheter featuring a split-tip design for dialysis, recognized for popularity and effectiveness in routine dialysis access applications
- Centros® Catheters: Custom-engineered central line hemodialysis catheters designed to prevent fibrous sheaths and other causes of catheter failures in long-term use
- 7% Sodium Citrate Catheter Locks: Pharmaceutical-grade catheter lock products with 7% sodium citrate formulated to maintain catheter patency and extend catheter viability
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ash Access Technology
DalCor Pharmaceuticals
HQ: Canada
Website
- Description: Provider of pharmacogenetic precision treatments for cardiovascular disease targeting patients with the ADCY9 AA genotype, including dalcetrapib; the completed Dal-GenE (DAL-301) cardiovascular outcomes trial; the Phase 3 Dal-GenE-2 (DAL-302) trial evaluating dalcetrapib’s potential to reduce fatal and non-fatal myocardial infarction; and the cobas ADCY9 genotype companion diagnostic developed with Roche Molecular Systems.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DalCor Pharmaceuticals company profile →
Cardionics
HQ: United States
Website
- Description: Provider of auscultation simulation products and services that support classroom education, clinical and telehealth programs in medical institutions and universities worldwide, including the SAM4 Auscultation Manikin, electronic stethoscopes (options for hearing-impaired users), Bionic Hybrid Simulator, SAM Online remote training, and telehealth systems for sharing live physiological sounds.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cardionics company profile →
NeoChord
HQ: United States
Website
- Description: Provider of devices and services for mitral valve repair on a beating heart, including the NeoChord DS1000 System for echo-guided restoration of damaged mitral valve chords through a small incision; NeoChord ConsultConnect and ConnectCARD consultation services for delivery of artificial chordae tendineae to aid treatment of mitral insufficiency; and the Transcatheter Transseptal NeoChord NeXuS for MRI safety under specific conditions post-treatment with NeoChord devices.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeoChord company profile →
InteloMed
HQ: United States
Website
- Description: Provider of non-invasive, real-time cardiopulmonary monitoring solutions. Offers InteloMed TeleHealth Technology that uses facial scans during virtual consultations to deliver pulse and respiration metrics to clinicians. Engages in a NASA-supported project to develop non-contact monitoring for personnel and conducts an IRB-reviewed clinical study to validate its algorithms against traditional methods.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InteloMed company profile →
Insightra
HQ: United States
Website
- Description: Provider of medical devices focused on hernia and other surgical therapies, including the Ultra 7Fr Intra-Aortic Balloon Catheter for cardiovascular interventions, offering a smaller 7Fr diameter with performance comparable to an 8Fr catheter, suitable for patients with reduced vessel size.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Insightra company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ash Access Technology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ash Access Technology
2.2 - Growth funds investing in similar companies to Ash Access Technology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ash Access Technology
4.2 - Public trading comparable groups for Ash Access Technology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →